MiR-7e-5p downregulation promotes transformation of low-grade follicular lymphoma to aggressive lymphoma by modulating an immunosuppressive stroma through the upregulation of FasL in M1 macrophages

Xiaoli Lou\textsuperscript{1,\textdagger}, Jianhong Fu\textsuperscript{3\textdagger}, Xin Zhao\textsuperscript{1}, Xuemei Zhuansun\textsuperscript{4}, Chao Rong\textsuperscript{1}, Maomin Sun\textsuperscript{4}, Hui Niu\textsuperscript{2}, Lei Wu\textsuperscript{4}, Yongsheng Zhang\textsuperscript{2}, Lu An\textsuperscript{7}, Lingchuan Guo\textsuperscript{5}, Shan Wan\textsuperscript{1,\textdaggerdbl} and Shouli Wang\textsuperscript{1,\textdaggerdbl}

Abstract

Background: In follicular lymphoma (FL), histologic transformation to high-grade FL and diffuse large B-cell lymphoma (DLBCL) is a critical adverse step in disease progression. Activation of the oncogene c-MYC and tumor microenvironment remodeling account for FL progression. A panel of microRNA (miRNA) was downregulated in transformed FL (tFL).

Methods: Differentially expressed miRNAs were systematically compared in 11 lymph nodes from patients at different stages of disease. Expression of miR-7e-5p was analyzed in 46 B-cell lymphomas, including 30 FL tissues and 16 DLBCL tissues. In FL cells, transcriptional regulation of the oncogene c-MYC on its target miR-7e-5p was revealed by Chromatin Immunoprecipitation (ChIP) assay. Exosome, carrying differentially expressed miR-7e-5p was isolated and visualized by transmission electron microscope and fluorescence tracing. The effect of miR-7e-5p on recipient macrophage was determined by target gene quantification, flow cytometry, and TUNEL method in a cocultured system with miR-7e-5p-mimics or inhibitors treatment. Expression of miR-7e-5p targets, macrophage proportions, and clinical parameters were included for correlation analysis.

(Continued on next page)
Background
Follicular lymphoma (FL), an indolent B-cell lymphoma, can histologically transform into high-grade FL and a highly aggressive malignancy, diffuse large B-cell lymphoma (DLBCL), under certain conditions. The malignant transformation of FL is considered an adverse step for patients and is associated with a much poorer clinical course and outcomes [1]. Transformation has been found to occur in approximately 30% of patients at 10 years, which is associated with a decline in survival to less than 2 years [1]. For this reason, understanding the pathogenesis of FL transformation is helpful for the prediction and treatment of FL patients. Accumulation of genetic alterations has been found to be important for FL transformation. For example, patients with follicular lymphoma always show more aggressive clinical outcomes with rearrangement of the oncogene MYC.

In addition to genetic alterations, the tumor microenvironment is another important aspect that affects FL progression [2]. Decreased subpopulations of CD4+/CD8+ T cells, macrophages and dendritic cells in patients are associated with FL transformation and are predictors of worse survival [2–4]. In a large cohort of 132 FL patients, elevated levels of programmed death ligand-2 (PD-L2) expression and reduced intratumoral immune infiltration were correlated with adverse outcome [5]. A more specific subgrouping of PD-1-positive cells, which further separates them into T follicular helper (TFH) cells and exhausted T cells, enables the prediction of acute progressive FL according to the ratio between TFH and exhausted T cells [2]. These population-based clinical data provide reliable evidence that the homeostasis of the immune microenvironment strongly influences the fate of FL.

Recently, exosomes have been found to act as essential mediators in the maintenance and modulation of the tumor microenvironment [6]. One of the active substances transported by exosomes is microRNA (miRNA), which is a single-stranded RNA that fine tunes the expression of target genes at the posttranscriptional level [7]. In addition to tumor parenchyma, miRNAs can also be produced by stromal cells, which in turn affects tumor growth and invasion [8]. In a mouse model, miR-298-5p from activated CD8+ T cells induced the apoptosis of mesenchymal stem cells, which prevented the formation of mesenchymal tumor stroma and tumor cell metastasis [8].

Exosomal miRNAs act as important mediators that maintain the tumor microenvironment and are regarded as potential therapeutic methods for different tumors [7, 8]. In the context of FL, a panel of miRNAs that includes miR-7e, miR-30a, and miR-199a has been found to be associated with disease progression [9, 10]. Specifically, miR-150 negatively regulates forkhead box transcription factor (FOX)-P1, which inhibits the progression of lymphoid malignancies, while miR-31 targets E2F transcription factor 2 (E2F2) and class II PI3 kinases (PIK3C2A) and inhibits tumor cell proliferation in FL [9, 10]. Although these studies reveal the tumor suppressive role of miRNAs, little is known about their function in modulating the tumor microenvironment. Given the diverse functions of miRNAs observed in other tumor types, certain miRNAs may contribute to the maintenance of microenvironmental homeostasis, which prevents the progression of FL.

In this study, we screened for miRNA candidates in patient tissues that play important roles in FL transformation. We identified miR-7e-5p, which was downregulated from indolent FL to high-grade FL and DLBCL. By using a coculture system and exosome isolation, we detected the transfer of miR-7e-5p from tumor cells to surrounding M1 macrophages. Repressed expression of miR-7e-5p led to the upregulation of FasL and activation of caspase signaling, which accounted for the apoptosis of M1 macrophages. Clinical data demonstrated the correlation of miR-7e-5p downregulation, upregulation of downstream targets and clinicopathologic features in FL transformation.

Materials and methods
All antibodies and RNA information were listed in Supplementary Table S1–S2.
**Patient samples**

Patient tissue samples used in this study were collected from lymph nodes, which were diagnosed as FL or DLBCL following the World Health Organization (WHO) guidelines [11]. Duodenal-type follicular lymphoma and other extranodal lymphomas were excluded. Eleven frozen neoplastic lymph node tissues, consisted of seven FL cases (grade 1: n = 2, grade 2: n = 1, grade 3A: n = 1, grade 3B: n = 3), and four DLBCL cases were examined for six candidate miRNAs. For miR-7e-5p quantification, frozen tissues from neoplastic lymph nodes (n = 46), including different stages of FL cases (n = 30) and DLBCL cases (n = 16) were collected from the first affiliated hospital of Soochow University. Histological assessment and grading of FL were determined by the proportion of centrocytes and centroblasts according to the WHO guidelines [11]. Different stages of FL consisted of grade 1 (n = 5), grade 2 (n = 8), grade 3A (n = 1), and grade 3B (n = 16). For immunohistological analysis, paraffin-embedded lymph node tissues from low-grade FL (n = 8) and high-grade FL (n = 8) were obtained from the secondary affiliated hospital of Soochow University. FL tissues included grade 1 (n = 1), grade 2 (n = 7), grade 3A (n = 3), and grade 3B (n = 5). Paired tissue samples (n = 5) were collected from FL patients transformed from a low-grade FL (grade 1 and grade 2) to a high-grade FL (grade 3A and 3B) or DLBCL. The project was approved by the ethics committee of Soochow University.

**Cell culture and transfection**

Human FL-like cell line WSU-NHL was cultured in RPMI supplemented (HyClone, Logan city, Utah, USA) with 20% fetal bovine serum (FCS, Gibco Life Technologies, Carlsbad, CA, USA) and 1% penicillin/streptomycin (Corning, Discovery Boulevard Manassas, VA, USA) at 37 °C in a 5% CO2 atmosphere (Wugang, Shanghai, China). Mouse B cell lymphoma cell line A20 cells was cultured in RPMI supplemented with 20% FCS and 1% penicillin/streptomycin at 37 °C.

Mimic for miR-7e-5p (Supplemental Table 2, Guangzhou RiboBio, Guangzhou, China) were synthesized and transfected into both WSU-NHL and A20 cells using Lipofectamine® 3000 (Life Technologies) according to the manufacturer’s protocol with a media change 6 h after transfection. Small-interfering RNAs (siRNAs) for miR-7e-5p (Supplemental Table 2, Guangzhou RiboBio) were transfected by using Lipofectamine® 3000 (Life Technologies). Cells transfected with nonsense siRNA served as controls. RNAs and proteins were extracted 48 to 72 h post-transfect and used for further analysis.

Aclarubicin, which belongs to the anthracycline family and inhibits cell proliferation by inhibiting topoisomerase, is widely used for the treatment of B-cell lymphoma [12]. For the apoptosis assay, mice macrophage cells were treated with Aclarubicin (Shenzhen Main Luck Pharmaceuticals Inc. Shenzhen, China) at the concentration of 2.7 μg/ml for 2 h. Dimethylsulphoxide (DMSO, Sigma-Aldrich, Saint Louis, Missouri, USA) treated cells was used as negative controls. Proteins were collected 48 h post-transfection to analyze the activation of caspase proteins. Cells were collected to determine the proportion of apoptotic cells by flow cytometry.

**Mouse experiment and macrophage isolation**

The setup of mouse experiments was approved by the institutional regulation of Model Animal Research Center of Soochow University (Suzhou, China). Operation and termination of mice were performed according to the criteria of the animal welfare office of Soochow University.

Macrophages from mouse were isolated at the age of 6 weeks. Mice were injected with 1 ml liquid paraffin intraperitoneally 3 days before isolation according to Ray’s method [13]. At the time of isolation, mice were euthanized and sterilized with 70% ethanol. It was immediately followed by the intraperitoneally injection of 5 ml cold RPMI using a 27 g needle. After gently massage the peritoneum, ascitic fluid was collected using a 25 g needle. Peritoneum was opened by incision and the remaining fluid was collected by Pasteur pipette. Cell suspension was washed once with cold PBS and treated with RBC lysis buffer (Beyotime, Shanghai, China) for 1 min to get rid of erythrocytes. Three hours after seedling, the adherent cells were gently washed once with PBS and cultured in full RPMI medium for further analysis. Enriched macrophages were identified and counted by flow cytometry (CytoFLEX, Beckman Coulter, CA, USA).

**Real-time PCR and Western blotting**

Isolation of miRNA from cultured cells was performed by using the HiPure Universal miRNA Kit (Magen biotechnology, Guangzhou, China). Total RNA was extracted from cells by 1 ml TRIZOL and miRNA were isolated according to the manufacturer’s instructions. To isolate miRNA from human tissues, 10 μm paraffin embedded tissues was deparaffinized by using xylene and followed by the isolation of miRNA using the MagMAX™ FFPE DNA/RNA Ultra Kit (Thermo Fisher Scientific, Woodward St, Austin). Proteins from cultured cells was extracted by using the 10x Cell lysis buffer (Cell Signaling Technology, MA, USA) and supplemented with 0.1 mM PMSF and proteinase-inhibitor (Cell Signaling Technology).

Reverse transcription for specific miRNAs was performed using 2 μg miRNA and respective primers for reverse transcription (listed in supplementary Table 2)
according to the Stem-loop method [14]. Quantitative real-time PCR were carried out using the ABSolute qPCR SYBR Green ROX Mix (Thermo Fisher Scientific) and the following cycling condition: 95 °C for 10 min, 40 cycles of 95 °C for 15 s, and 60 °C for 60 s. StepOne Plus device (Thermo Fisher Scientific) was used for the detection. The small nuclearRNA U6 was used for normalization.

For Western blotting, 30 μg total proteins measured by BCA assay (Beyotime) was separated in sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis and transferred to a PVDF membrane (Merck Millipore, MA, USA). It was followed by blocking the membrane with 5% skim milk in TBST (Tris-buffered saline/0.1% Tween 20). Membranes were incubated with primary antibody at 4 °C overnight and followed by the incubation of HRP-conjugated secondary antibody in skim milk (1:5000; Boster, Wuhan, China). Electronic chemical Laboratory (ECL) detection kit was used for the signal development (Merck Millipore).

Chromatin Immunoprecipitation (ChIP)
After transfection, 1 × 10^7 Cells in cultured T75 cell culture flask were collected and incubated with formaldehyde/PBS (1%) for 12 min to allow cross-linking of DNA and protein according to a ChIP protocol previously described [15]. Protein in the complex was diluted to 1 mg/ml with RIPA buffer and pre-cleared with 30 μl of Dynabeads Protein G (Nanoeast Biotech, Jiangsu, China). Another tube of 50 μl Dynabeads Protein G beads was blocked with 15 μg sperm DNA and 50 μg BSA. Pre-cleared samples were incubated with blocked Dynabeads and 4 μg primary antibody at 4 °C overnight to allow precipitation. The resulting immunocomplex-bound beads were washed carefully with RIPA buffer and resuspended in TE buffer. Reversal crosslinking was achieved by incubation the complex in 4 M NaCl at 65 °C for 5 h. DNA was extracted and prepared for real-time PCR analysis. Precipitated promoter fragments were normalized to a standard curve of genomic DNA. Primers binding to an unspecific sequence of genomic DNA was used as a negative control (listed in supplementary Table 2).

Immunohistochemistry (IHC)
Immunohistochemical staining was carried out in paraffin embedded tissue from lymphoma patients. Tissue sections were deparaffinized and rehydrated by the following wash steps: 3 × 5 min xylene, 2 × 3 min 100% ethanol, 3 min 95% ethanol, 3 min 75% ethanol, and finally rinsing with aqua dest. 10 mM sodium citrate buffer (pH 6.0) (Boster, Wuhan, China) was incubated with tissue sections by microwave twice for 15 min. After retrieval of antigens, tissue sections were incubated with 30% peroxidase (Yonghua chemical technology, Jiangsu, China) for 10 min and blocked with 5% BSA-confining-liquid for 20 min (Boster) and incubated with primary antibody at 4 °C overnight. Tissue sections were incubated with a biotinylated anti-rabbit secondary antibody (Boster) for 2 h. Streptavidin–HRP (Boster) and Peroxidase Substrate (DAB) solution (MXB Biotechnologies, Fuzhou, China) were added to the tissue sections for signal development.

All IHC stains of lymphoma tissues were defined by two pathologist (H.N and LL.G) according to the intensity and percentage of positive tumor cells. Intensity was analyzed: 0 = negative, 1 = low nuclear stain, 2 = medium nuclear stain, 3 = strong nuclear stain. Percentage of positivity was defined: 0 = no positive cells, 1 = less than 1%, 2 = less than 10%, 3 = 10–50%, 4 = more than 50%. Final scoring was multiplying of qualitative and quantitative parameters.

Flow Cytometry
For FACS analysis, macrophages in cell culture were detached with 0.25% trypsin (Gibco) to achieve a single-cell suspension in PBS solution. Followed by three times washing with PBS supplemented with 2% of FBS, cells were incubated with relevant antibodies or reagents. For the detection of different types of macrophages, isolated cell suspension was incubated with F4/80, CD11b, and CD86 antibodies for 30 min. After three times of washing with PBS, 1 × 10^5 cells were resuspended in 100 μL PBS, and analyzed on flow cytometer (CytoFLEX, Beckman Coulter, CA, USA). Differentiated macrophages were identified by bright co-expression of F4/80 and CD11b. M1 macrophage was identified by the CD86^+ population. Cell apoptosis analysis was performed using Annexin V-FITC Apoptosis Detection Kit (Beyotime), according to manufacturer’s instructions. For apoptosis analysis, 1 × 10^5 cells were incubated with 5 μL fluorescein isothiocyanate (FITC)-labeled Annexin V and 10 μL propidium iodide (PI) for 20 min at room temperature (RT) in PBS containing 2% FBS. F4/80 was used as the marker for the gating of macrophages. Early apoptotic cells displayed a bright Annexin V and a dim PI, while late apoptotic cells had intensive stain of both reagents. Annexin V+/PI- events were acquired for the analysis of early apoptosis, while Annexin V+/PI+ events were used for the analysis of late apoptosis. Compensation control for negative population was achieved by incubation with each antibody/dye in separate vials. Data were analyzed using the CytExpert software (Ver. 2.3.0.84, CytExpert, Beckman Coulter, Inc).

Data acquisition and statistical analysis
The data are presented as mean ± SD. Protein quantification after Western blotting was achieved by using the SkanIT™ Software (Thermo Fisher Scientific). Comparison of
miRNA and proteins levels between non-paired groups were done by the nonparametric Mann-Whitney U test. Comparison of miRNA expression between paired groups of patients relied on the $t$-test. Significance levels were as following: $P < 0.05$, $P < 0.01$, and $P < 0.001$ (IBM SPSS Statistics 19.0, Armonk, NY, USA). Experiments were repeated three times for statistical analysis.

Results
miR-7e-5p is downregulated in FL progression to high-grade FL and DLBCL
To identify miRNAs that may affect the transformation of indolent FL to high-grade FL and DLBCL, six miRNAs (miR-30a, miR-31, miR-20c, miR-501, miR-199a and miR-7e-5p) previously shown to be dramatically downregulated in FL transformation were selected as our candidates [10]. Tissue samples from different stages of FL ($n = 7$), which consisted of grade 1 ($n = 2$), grade 2 ($n = 1$), grade 3A ($n = 1$), and grade 3B ($n = 3$) were collected according to the WHO grading system [11]. Together with DLBCL, lymphoma tissues were divided into three groups, namely low-grade FL (grade 1–2, $n = 3$), high-grade FL (grade 3A and 3B, $n = 4$), and DLBCL ($n = 4$). All six of these miRNAs were downregulated in DLBCL compared with low-grade FL (Fig. 1a and Supporting Figure S1). Among the six miRNAs, miR-7e-5p showed trend of downregulation in both high-grade FL (fold change = 0.51, $P = 0.077$) and DLBCL (fold change = 0.39, $P < 0.05$) compared with low-grade FL, which suggests its role in the early stages of transformation. To validate the relevance of miR-7e-5p in the progression of lymphoma, we increased the number of samples from different stages (grade 1: $n = 5$, grade 2: $n = 8$, grade 3A: $n = 1$, grade 3B: $n = 16$, and DLBCL: $n = 16$), and miR-7e-5p was found to be significantly downregulated in DLBCL compared with low-grade FL (fold change = 0.04, $P < 0.05$), and compared with high-grade FL (fold change = 0.28, $P < 0.05$; Fig. 1b). However, the differential expression of miR-7e-5p was not detected between high-grade FL and low-grade FL. To avoid heterogeneity among patients, we further analyzed the expression of miR-7e-5p in five paired FL-tFL samples.
in this cohort, miR-7e-5p was dramatically downregulated in the tFL samples compared with FL samples (fold change = 0.19, P < 0.001).

To further analyze the function of miR-7e-5p in FL progression in vitro, miRNA expression was compared in different lymphoma cell lines, namely, DLBCL cell lines (OCI-LY3, SUDHL-8, TMD-8, and Farage), FL cell lines (DoHH-2 and WSU-NHL), mantle cell lymphoma (JeKo-1) and Burkitt’s lymphoma (Daudi). As expected, the levels of miR-7e-5p were much higher in the FL cell lines than in the DLBCL cell lines (fold change = 4.89, P < 0.001; Fig. 1d). Taken together, these data revealed the potential role of miR-7e-5p in the suppression of the transformation of low-grade FL to high-grade FL and DLBCL.

miR-7e-5p is negatively regulated by c-MYC during FL transformation

Genetic amplification of the oncogene c-MYC has been found to be a critical step of FL transformation via the induction of tumor growth and chromosomal instability [16]. Previously, c-MYC has been reported to regulate the expression of miR-7e-5p at the transcriptional level in cancer cell lines [17, 18]. We next analyzed the relevance of c-MYC in regulating miR-7e-5p expression in the progression of lymphoma. In WSU-NHL cells, quantitative PCR (q-PCR) revealed a 2.57-fold increase in miR-7e-5p expression after the inhibition of c-MYC by siRNA (P < 0.001; Fig. 2a and Supporting Figure S2). To test whether c-MYC regulates miR-7e-5p expression through direct interaction during transcription, a potential binding site of c-MYC in the promoter region of miR-7e (Fig. 2b; position – 17 to – 6) was predicted according to the JASPAR database [19]. Q-PCR of chromatin immunoprecipitation eluates revealed amplification of the promoter region of miR-7e compared to negative control (fold change = 3.69, P < 0.01), which was not detectable when c-MYC expression was inhibited by siRNA treatment. Primers detecting Carbamoyl-
Phosphate Synthetase-2 (CAD) served as the positive control for ChIP analysis. This indicates that miR-7e-5p is transcriptionally downregulated by c-MYC in WSU-NHL cells (Fig. 2b).

To confirm the relevance of c-MYC in the transformation of FL, c-MYC protein levels were detected in five paired samples from available patient tissues (Fig. 2c). Tumor tissues from tFL samples had strong c-MYC staining in the majority cells (> 40% cell positivity), while FL samples had weak or negative staining (0–10% cell positivity; Fig. 2c). Elevated expression of nuclear c-MYC was detected during FL transformation ($P < 0.001$; Fig. 2d). Taken together, these data demonstrate that miR-7e-5p is negatively regulated by c-MYC through direct binding to the miR-7e-5p promoter region during FL transformation.

Exosomes mediate the transfer of miR-7e-5p from tumor cells to macrophages
Remodeling of the tumor microenvironment has been shown to be an aspect as equally important as genetic modification in FL progression and is characterized by inactivation of cytotoxic T cells and macrophages and elevated levels of TFH cells [2, 3, 20]. We hypothesized that miR-7e-5p produced by tumor cells changes the immune context of FL, which may facilitate the survival of tumor cells. Previously, researchers found that lymphoma cells can modulate the phagocytic activity of classically activated macrophages (also known as M1 macrophages) [21]. To determine whether miR-7e-5p is responsible for the regulation of M1 macrophages, Cy3-labeled miR-7e-5p-mimics were transfected into the mouse lymphoma cell line A20, and the cells were then
coincubated with mouse macrophages in a Transwell system with 0.4 μm pores. Flow cytometry analysis demonstrated that the majority (91.6%) of peritoneal macrophages were of the M1 phenotype (Supporting Figure S4). After 24 h of coincubation, obvious red fluorescence was detected in the cytoplasm of macrophages, demonstrating the transfer of miR-7e-5p-mimics into macrophages by lymphoma cell-derived particles (Fig. 3a).

Next, we evaluated whether exosomes were responsible for the transport of miR-7e-5p in the tumor microenvironment. Exosomes isolated from the supernatant of A20 cells were identified and visualized by transmission electron microscopy (Fig. 3b) and NanoSight particle tracking analysis (Fig. 3c). After transfection of miR-7e-5p-mimics or inhibitors into A20 cells, exosomes carrying higher or lower levels of miR-7e-5p were collected and confirmed to express exosome markers (CD63 and CD81) by Western immunoblotting (Supporting Figure S6). Real-time PCR detected increased levels of mature miR-7e-5p in macrophages treated with exosomes carrying miR-7e-5p-mimics (fold change = 15, P < 0.01), whereas a reduced level of mature miR-7e-5p was detected in macrophages when its expression in lymphoma cells was inhibited by miR-7e-5p inhibitors (fold change = 0.05, P < 0.001; Fig. 3d and Supporting Figure S3). Taken together, these results demonstrate that miR-7e-5p was delivered from lymphoma cells to recipient macrophages.

Exosomal miR-7e-5p inhibits FasL expression and inactivates the apoptotic pathway in stromal macrophages

To identify the target genes of miR-7e-5p, three miRNA target prediction databases (miRTarBase, TargetScan, and miRDB) were used for the identification of miR-7e-5p targets [22, 23]. Fifty-three potential target genes were found in all three databases, among which 21 had clear biological functions in cellular processes [24]. We further analyzed the relevance of the potential target genes in leukemia and lymphoma according to the GCBI database. Seven genes were associated with patient prognosis, among which Fas ligand (FasL), N-myc proto-oncogene protein (MYCN), and insulin-like growth factor 1 receptor (IGF1R) were associated with cell death and apoptosis (Fig. 4a).
Fig. 5 (See legend on next page.)
FasL is a strong apoptotic factor that binds to its receptors to activate the caspase cascade and regulate the activation of proteins involved in cell proliferation (Holler et al., 2003). To evaluate the effect of miR-7e-5p on FasL expression, macrophages isolated from mice were coincubated with A20 cells previously transfected with miR-7e-5p-mimics or inhibitors. Western blotting detected a slight increase of FasL and weak cleavage of poly-ADP-ribosyltransferase (PARP) in macrophages when coincubated with inhibitors-treated A20 cells (Supporting Figure S5). With the presence of aclarubicin added to A20 cells for 24 h to inhibit exosome secretion, a high level of exosomal miR-7e-5p was observed during the disease transformation (low-grade FL: n = 8, high-grade FL: n = 8, P < 0.05; Fig. 6b). In the tumor stroma, a decrease of M1 macrophages, an induction of M2 macrophages and an upregulation of miR-7e-5p downstream targets (FasL, Caspase 3 and Caspase 8) were detected in high-grade FL (Fig. 6c). The proportion of M1 macrophages was significantly lower; and the expression of miR-7e-5p target genes was higher in high-grade FL than in low-grade FL (low-grade FL: n = 8, high-grade FL: n = 8; Fig. 6d). Moreover, overexpression of miR-7e-5p was associated with unfavorable clinicopathological factors, including B symptoms and higher serum LDH levels (n = 46, P < 0.01; Table 1). These findings demonstrate that the decreased expression of miR-7e-5p is associated with the induction of FasL and apoptotic signaling in stromal immune cells, which leads to poorer clinical outcomes in FL patients.
Fig. 6 (See legend on next page.)
Discussion
The transformation of FL in 30% of patients to high-grade FL and DLBCL is widely accepted as an adverse event that dramatically reduces patient survival [1]. The decreased expression of different miRNAs, including miR-31, miR-7e, miR-30a and miR-199a, is associated with rapid disease progression, and these miRNAs are regarded as potential tumor suppressors in FL transformation [9, 10]. However, the underlying mechanisms by which miRNAs inhibit the malignant transformation of FL remain unclear. In this study, we found that miR-7e-5p is downregulated in lymphoma cells during the transformation of FL, which is responsible for the remodeling of the tumor microenvironment via the induction of immune escape and tumor progression.

The oncogene c-MYC is located at chromosome 8q24, which is amplified and translocated in 5 to 15% of DLBCL [25]. During the transformation of FL to high-grade FL and DLBCL, c-MYC is activated and consequently induces a subset of target genes involved in promoting cell growth and inhibiting apoptosis [16, 26]. Previously, let-7 family miRNAs were found to be widely repressed by c-MYC in B cell lymphoma [26]. The transcriptional regulation of miR-7e-5p by c-MYC was identified by an in vitro affinity purification approach in HEK293 cells [17]. In this study, we confirmed the direct binding of c-MYC to the miR-7e-5p promoter, which negatively regulated the transcription of miR-7e-5p and its tumor-suppressive activity in the transformation of FL. Therefore, the downregulation of miR-7e-5p during the transformation of FL to DLBCL can be explained by c-MYC amplification.

We demonstrated the downregulation of miR-7e-5p in high-grade FL and DLBCL, which contributes to disease progression. The tumor suppressor role of miRNAs can be achieved by the direct inhibition of oncogenes in tumor cells and the regulation of the tumor cell microenvironment through exosome secretion [7, 8]. Our results reveal the importance of exosomes in mediating the transfer of miRNA from tumor cells to stromal cells. In the Transwell coculture system, miR-7e-5p was transferred from mouse lymphoma cells to macrophages. In this context, downregulation of miR-7e-5p in lymphoma cells led to a reduced amount of miR-7e-5p in surrounding macrophages.

Table 1 Correlation of miR-7e-5p expression. With clinicopathological variables in 46 cases

| Variables          | miR-7e-5p expression | P-value |
|--------------------|----------------------|---------|
|                    | Total cases          | Low expression(%) | High expression(%) |
| Age (years)        |                      |         |                   |
| <=60               | 28                   | 21 (56.8%) | 7 (77.8%)         | 0.221 |
| >60                | 18                   | 16 (43.2%) | 2 (22.2%)         |       |
| Sex                |                      |         |                   |
| Male               | 29                   | 23 (62.2%) | 6 (66.7%)         | 0.561 |
| Female             | 17                   | 14 (37.8%) | 3 (33.3%)         |       |
| B symptom          |                      |         |                   |
| No                 | 29                   | 20 (54.1%) | 9 (100.0%)        | 0.009 |
| Yes                | 17                   | 17 (45.9%) | 0 (0%)            |       |
| Serum LDH          |                      |         |                   |
| Normal (<=225)     | 28                   | 19 (51.4%) | 9 (100.0%)        | 0.006 |
| High (>225)        | 18                   | 18 (48.7%) | 0 (0%)            |       |
| Relapse or die in 5 years |      |         |                   |
| No                 | 40                   | 31 (83.8%) | 9 (100.0%)        | 0.248 |
| Yes                | 6                    | 6 (16.2%) | 0 (0%)            |       |

**Abbreviations:** LDH lactic dehydrogenase. P values in bold are significant at P<0.05
Therefore, miR-7e-5p expressed in normal tissue and indolent FL may function as a tumor suppressor; however, downregulation of miR-7e-5p in the transformation of lymphoma reduces the amount of miR-7e-5p and its function in recipient macrophages (Fig. 7).

Based on miRNA databases and enrichment analysis, FasL was selected as a potential target gene of miR-7e-5p. FasL belongs to the tumor necrosis factor (TNF) family, which interacts with and activates Fas receptor (Fas) and induces the caspase cascade during cellular apoptosis [27]. By binding to its ligand, the intracellular death domain of Fas interacts with each other and serves as a platform for the initiation of apoptosis through the enrichment of Caspase-8 protein [28]. After dimerization, Caspase-8 undergoes autocatalytic cleavage and triggers the activation of Caspase-3 and Caspase-7, which affects the function of many genes (e.g., PARP) involved in cell proliferation and transformation [28]. As expected, we detected an inhibition of FasL expression at both the transcriptional and protein levels in recipient macrophages with elevated exosomal miR-7e-5p levels in the stroma. Consequently, the cleavage of PARP was reduced in the coinoculation experimental setup with miR-7e-5p-mimic overexpression. Interestingly, the reduction in cleaved PARP and cleaved Caspase-3 was more obvious in macrophages treated with isolated exomes containing a high level of miR-7e-5p. The negative regulation of macrophage apoptosis by exosomal miR-7e-5p was demonstrated by FACS analysis and in situ TUNEL assays. Overall, sufficient exosomal miR-7e-5p facilitates the survival of macrophages. The decreased production of exosomal miR-7e-5p in lymphoma cells activates apoptotic signaling via its target FasL in stromal macrophages (Fig. 7).

Although FasL is upregulated by the suppressive effect of miR-7e-5p during FL transformation, it probably cannot activate the apoptosis of lymphoma cells due to multiple immune escape mechanisms [2]. Loss of Fas is present in 17% of FL and 51% of DLBCL, while the death domain of FAS is mutated in 6% of FL and 20% of DLBCL, which leads to inactivation of the Fas-mediated apoptotic signaling pathway [29]. However, upregulation of FasL in macrophages according to our results induces immune suppression due to the Fas-FasL interaction. In addition, FasL was previously found to bind to and form a hexamer with cytotoxic T lymphocyte associated protein 4 (CTLA4), which abrogated costimulation by binding to B7 receptor-expressing immune cells [30]. Thus, FasL induces a strong apoptotic signal not only by activating the caspase cascade but also by switching off...
antiapoptotic signaling in immune cells [30]. Our clinical data demonstrated that repression of miR-7e-5p was associated with the upregulation of FasL and apoptotic signaling in M1 macrophages, accounting for poorer clinical outcomes.

In FL and DLBCL, the translocation and activation of c-MYC and B-cell lymphoma 2 (BCI2) is regarded as “double-hit lymphoma” because of the poor survival of patients with this pattern of genetic alteration [31]. In FL, t (14; 18) was reported in 96% of patients, which was associated with activation of BCI2 and apoptosis inhibition [29]. Our results demonstrate that the activation of c-MYC in lymphoma cells drives immune suppression through the downregulation of exosomal miRNA-7e-5p and activation of FAS-mediated apoptosis in macrophages. In this manner, the oncogene c-MYC not only promotes tumor cell proliferation but also collaborates with the antiapoptotic factor BCI2 in escaping immune surveillance by nearby immune cells. For the treatment of FL, aclarubicin inhibits DNA replication in cells and is currently used as a standard chemotherapy for patients [32]. The effects of FasL expression and cell apoptosis in macrophages were performed under aclarubicin treatment to mimic the situation in the clinic, which revealed the importance of considering the immune microenvironment when planning appropriate treatment for FL patients.

Conclusion
In summary, our study revealed the downregulation of miR-7e-5p during the transformation of FL to aggressive lymphoma. In tumor microenvironment, miR-7e-5p was transferred from lymphoma cells to stromal macrophage via exosome. In stromal M1 macrophages, reduced miR-7e-5p level led to the upregulation of FasL, the activation of caspase signaling, and the cleavage of PARP protein, which promoted macrophage apoptosis. In patient tissues, upregulation of FasL and activation of caspase signaling was detected in tumor stromal macrophages. The downregulation of miR-7e-5p correlated with poorer clinical outcomes. These findings indicated potential therapeutic function of miR-7e-5p in restoring macrophage surveillance against FL progression.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13046-020-01747-z.

Additional file 1: Supporting Figure S1. Relative miRNA expression in low-grade FL, high-grade FL and DLBCL. Statistical test: Mann-Whitney U test.

Additional file 2: Supporting Figure S2. The expression level of c-MYC after transfecting three different siRNA sequences. A) Western blotting indicating the protein levels of c-MYC after siRNA inhibition. B) Real-time PCR indicating the mRNA levels of c-MYC after siRNA treatment. Statistical test: t-test.

Additional file 3: Supporting Figure S3. Verification of efficiency of miR-7e-5p-mimics and inhibitors treatment. Left: The level of miR-7e-5p expression increased significantly after treatment of miR-7e-5p-mimics. Right: Lower expression level of miR-7e-5p was detected after transfection of the miR-7e-5p inhibitors. Statistical test: t-test.

Additional file 4: Supporting Figure S4. FACS analysis of cell types isolated from mouse abdominal. Left: population of cells with F4/80 and CD11b co-expression (41%). Right: histogram of CD86+ events indicating the population of M1 macrophages.

Additional file 5: Supporting Figure S5. Effect of miR-7e-5p expression of A20 cells on apoptotic signaling in macrophages. Western blotting detecting FASL, PARP, cleaved PARP in macrophages. The macrophages were cocultured with miR-7e-5p-mimics or inhibitors-treated A20 cells. Macrophages were pretreated with DMSO as the negative control for aclarubicin.

Additional file 6: Supporting Figure S6. Expression of CD81 and CD63 in exosomes from A20 cells. CD81 (30 kDa) and CD63 (35 kDa) protein levels in the exosomes from A20 cells, which were treated with miR-7e-5p-mimics or inhibitors. Transferrin (80 kDa) seved as a loading control. GW4869 was used to inhibit exosome secretion from A20 cells.

Additional file 7: Supplementary Table S1. Antibodies.

Additional file 8: Supplementary Table S2. Primers and siRNAs

Abbreviations
FL: Follicular lymphoma; tFL: transformed follicular lymphoma; DLBCL: Diffuse large B-cell lymphoma; FasL: Fas ligand; PARP: Poly-ADP-ribosyltransferase

Acknowledgements
Tissue samples were provided by the tissue bank of the Second Affiliated Hospital of Soochow University (Suzhou, China) with the approval of the Ethics Committee of the Soochow University. We thank Sanitation and Environment Technology Institute of Soochow University and Fei Zhao and Yue Wu for their support of immunohistological staining. We thank Equipment Sharing Platform of Soochow University Institutes for Translational Medicine and Zhonglin Fu for technical support of flow cytometry.

Authors’ contributions
XL performed experiments, analyzed, and interpreted data. J.F. analyzed data and provided samples and clinical data. X. Zhao, X. Zhansun, L.W. and L.A. performed mouse experiments. C.R., M.S., L.G. and Y.Z. analyzed data and provided samples and clinical data. X. Zhao, X. Zhansun, L.W. and L.A. performed mouse experiments. C.R., M.S., L.G. and Y.Z. analyzed immunohistology data. X.L. performed experiments, analyzed, and interpreted data. J.F. analyzed data and provided samples and clinical data. X. Zhao, X. Zhansun, L.W. and L.A. performed mouse experiments. C.R., M.S., L.G. and Y.Z. analyzed immunohistology data. H.N. provided tissue samples. S. Wan designed experiments and wrote the paper. S. Wang designed the study. All authors edited the paper for submission. The author(s) read and approved the final manuscript.

Funding
This study was supported by a grant from Collaborative Innovation Center of Clinical Immunology between Soochow University and Sihong People’s Hospital, Jiangsu P. R. China, the Priority Academic Program Development of Jiangsu Higher Education Institutions, the National Science Foundation of the Jiangsu Higher Education Institutions of China (Grant No. 18KJB320017), the Youth Program of National Natural Science Foundation of China No. 81902400 (to S. Wan), the Priority Academic Program Development of Jiangsu Higher Education Institutions and Scientific Research Project of Jiangsu Health Commission (Grant No. H2018033).

Availability of data and materials
Additional Supporting Information are provided in Supporting Figure 1, 2, 3, 4, 5, 6. Antibodies, sequence for miRNA mimics, inhibitors and primers are listed in Supporting Table S1–S2.

Ethics approval and consent to participate
Tissue samples and clinical data collection were approved by the Ethics Committee of the Soochow University (Suzhou, China). Mouse experiments...
were also approved by the Ethics Committee of the Soochow University (Suzuou, China).

Consent for publication
Written informed consent for publication was obtained from all participants.

Competing interests
The authors disclose no potential conflicts of interest.

Author details
1Department of Pathology, School of Biology & Basic Medical Sciences, Soochow University, Suzhou 215123, China. 2Department of Pathology, the Second Affiliated Hospital of Soochow University, Suzhou 215004, China. 3Department of Hematology, the First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Soochow University, Suzhou 215006, China. 4Laboratory Animal Research Center, Soochow University School of Medicine, Suzhou 215123, China. 5Department of Pathology, the First Affiliated Hospital of Soochow University, Suzhou 215006, China. 6Collaborative Innovation Center of Clinical Immunology between Soochow University and Sihong People’s Hospital, Sihong 223900, China.

Received: 30 June 2020 Accepted: 22 October 2020
Published online: 09 November 2020

References
1. Montoto S, Fitzgibbon J. Transformation of indolent B-cell lymphomas. J Clin Oncol. 2011;29(14):1827–34.
2. Smeltzer JP, Jones JM, Zierer SC, Grote DM, Xu B, Ristow KM, et al. Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma. Clin Cancer Res. 2014;20(11):2862–72.
3. Wahlin BE, Aggarwal M, Montes-Moreno S, Gonzalez LF, Roncador G, Sanchez-Verde L, et al. A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1–positive, regulatory, cytotoxic, and helper T cells and macrophages. Clin Cancer Res. 2010;16(2):637–50.
4. Wang J, Tian S, Sun J, Zhang J, Lin L, Hu C. The presence of tumour-infiltrating lymphocytes (TILs) and the ratios between different subsets serve as prognostic factors in advanced hypopharyngeal squamous cell carcinoma. BMC Cancer. 2020;20(1):731.
5. Tobi NWD, Keane C, Guanawardana J, Mollee P, Birch S, Hoang T, et al. Progression of disease within 24 months in follicular lymphoma is associated with reduced Intratumoral immune infiltration. J Clin Oncol. 2019;37(34):3800–9.
6. Robbins PD, Morelli AE. Regulation of immune responses by extracellular vesicles. Nat Rev Immunol. 2014;14(3):195–208.
7. Filippazzi P, Burdick M, Villa A, Rivoltini L, Huber V. Recent advances on the role of tumor exosomes in immunosuppression and disease progression. Semin Cancer Biol. 2012;22(4):342–9.
8. Seo N, Shiakura Y, Tahara Y, Momose F, Harada N, Ikeda H, et al. Activated CD8+ T cell extracellular vesicles prevent tumour progression by targeting of leisional mesenchymal cells. Nat Commun. 2018;9(1):1435.
9. Musilova K, Devan J, Cerna K, Seda V, Pavlasova G, Sharma S, et al. miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels. Blood. 2018;132(22):2389–400.
10. Thompson MA, Edmonds MD, Liang S, McClintock-Treen S, Wang X, Li S, et al. miR-31 and miR-17-5p levels change during transformation of follicular lymphoma. Hum Pathol. 2016;50:118–26.
11. Jaffe ES, Barr PM, Smith SM. Understanding the new WHO classification of lymphoid malignancies: why it’s important and how it will affect practice. Ann Soc Clin Oncol Educ Book. 2017;37:535–46.
12. Pang B, de Jong J, Qiao X, Wessels LF, Neefjes J. Chemical profiling of the genome with anti-cancer drugs defines target specificities. Nat Chem Biol. 2011;7(7):472–80.
13. Ray A, Dittel BN. Isolation of mouse peritoneal cavity cells. J Vis Exp. 2010(35):1488.
14. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 2005;33(20):e179.
15. Wan S, Meyer AS, Weiler SME, Rupp C, Toth M, Sticht C, et al. Cytoplastic localization of the cell polarity factor scribble supports liver tumor formation and tumor cell invasiveness. Hepatology. 2018;67(3):1842–56.
16. Pasqualucci L, Khaihanan H, Fangazio M, Vastigha M, Messina M, Holmes AB, et al. Genetics of follicular lymphoma transformation. Cell Rep. 2014;6(1):130–40.
17. Braun JJ, Misia D, Busch B, Krohn K, Huttelmaier S. Rapid identification of regulatory microRNAs by miTRAP (miRNA trapping by RNA in vitro affinity purification). Nucleic Acids Res. 2014;42(8):e66.
18. Bezui L, Chuang AW, Liu P, Kroemer G, Kepp O. Immunological Effects of Epigenetic Modifiers. Cancers (Basel). 2019;11(12):1911.
19. Fornes O, Castro-Mondragon JA, Khan A, van der Lee R, Zhang X, Richmond PA, et al. JASPAR 2020: update of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 2019;48(D1):D87–D92.
20. Saifi M, Maran A, Raynaud P, Picot MC, Quittet P, Cartron G, et al. High ratio of interfollicular CD8/FOXP3-positive regulatory T cells is associated with a high FLIPI index and poor overall survival in follicular lymphoma. Exp Ther Med. 2010;16(6):933–8.
21. Voss J, Ford CA, Petrova S, Melville L, Paterson M, Pound JD, et al. Modulation of macrophage antitumor potential by apoptotic lymphoma cells. Cell Death Differ. 2017;24(6):971–83.
22. Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. Elife. 2015;4:e05005.
23. Zhou CH, Shrestha S, Yang CD, Chang NW, Lin YL, Liao KH, et al. miR TarBase update 2018: a resource for experimentally validated microRNA-target interactions. Nucleic Acids Res. 2019;47(D1):D296–D302.
24. Mi H, Muralaguraju A, Ebert D, Huang X, Thomas PD. PANTHER version 14: more genomes, a new PANTHER GO-slim and improvements in enrichment analysis tools. Nucleic Acids Res. 2019;47(D1):D419–D426.
25. Yoon SO, Jeon YK, Paik JH, Kim WJ, Kim YA, Kim JE, et al. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal Centre-like B (GCB) type. Histopathology. 2008;53(2):205–17.
26. Chang TC, Zeieils LR, Hwang HW, Chivukula RR, Wentzel EA, Dess M, et al. Lin-28b transactivation is necessary for Myc-mediated let-7 repression and proliferation. Proc Natl Acad Sci U S A. 2009;106(9):3384–9.
27. Holler N, Tardivel A, Kovacsovics-Bankowski M, Hertig S, Gaide O, Martinon F, et al. Two adjacent trimERIC Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol Cell Biol. 2003;23(4):1428–40.
28. Green DR, Llambi F. Cell Death Signaling. Cold Spring Harb Perspect Biol. 2015;7(12):abi06080.
29. de Charette M, Houtot R. Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy. Haematologica. 2018;103(8):1256–68.
30. Aronin A, Arnsi S, Prizognina TB, Tzakda K, Shen R, Grimmann L, et al. Highly efficient, in-vivo Fas-mediated apoptosis of B-cell lymphoma by hexameric CTLA4-Fas-1. J Hematol Oncol. 2014;7:64.
31. Sarkozy C, Traverse-Glehen A, Coiffier B. Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas. Lancet Oncol. 2015;16(15):e55–e67.
32. Chen L, Yin Q, M R, Wei X, CHAG priming regimen containing of cytarabine, aclacinomycin homoharringtonine and G-CSF for relapsed refractory acute myelogenous leukemia: a modified combination chemotherapeutic combination. Leuk Lymphoma. 2013;54(10):2291–3.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.